Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection
Learn more about:
Related Clinical Trial
Assessment of Recombinant HAT-RDT Specificity
Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring
Prospective Evaluation of an RDT to Screen for Gambiense HAT and Diagnose P. Falciparum Malaria
Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection
Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: Early Test-of-cure
Trial of DB289 for the Treatment of Stage I African Trypanosomiasis